Related Experiment Video

Updated: Oct 21, 2025

An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

11.2K

Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting

Annalisa Pappalardo1,2, Emilio Francesco Giunta1,2, Giuseppe Tirino2

  • 1Medical Oncology Unit, Ospedale del Mare, Naples, Italy.

Frontiers in Oncology
|September 6, 2021
PubMed

Insights

Pancreatic ductal adenocarcinoma (PDAC) remains lethal due to metastasis. This review explores current and novel therapeutic strategies, including targeted therapies and neoadjuvant treatments, for early-stage PDAC to improve patient survival.

Area of Science:

  • Oncology
  • Gastroenterology
  • Cancer Research

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, largely due to early metastasis.
  • Despite treatment advances, localized PDAC often fails therapeutically because of limited understanding of its pathology.
  • Metastasis remains a significant challenge in treating early-stage pancreatic cancer.

Purpose of the Study:

  • To review current treatment strategies for early-stage PDAC.
  • To explore emerging preclinical and clinical therapeutic approaches for PDAC.
  • To examine targeted therapies and neoadjuvant treatments' impact on localized PDAC survival.

Main Methods:

  • This is a narrative review.
  • Literature search on preclinical and clinical studies.
  • Analysis of targeted therapies and neoadjuvant treatment effects.

Main Results:

  • Current treatments for early-stage PDAC show limited success due to metastatic potential.
  • Research is advancing personalized approaches using biomarkers and novel therapeutic targets.
  • Neoadjuvant treatments and targeted therapies show promise in improving survival outcomes.

Conclusions:

  • Improved understanding of PDAC pathology is crucial for effective treatment.
  • Personalized medicine, biomarkers, and novel targets are key for future PDAC therapies.
  • Further investigation into neoadjuvant and targeted treatments is warranted for localized PDAC.
Keywords:
PARPiPDAC - pancreatic ductal adenocarcinomabiomarkersctDNA = circulating tumor DNAgemcitabineneoadjuvant chemotherapypredictive factorstarget therapy

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.0K
Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer Using In-Situ No-Touch Isolation Technique08:12

Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer Using In-Situ No-Touch Isolation Technique

Published on: February 2, 2022

2.2K

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
145
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
759